GILL JOHN 4

What Happened
John Gill, a member of Altimmune's board of directors, was granted derivative awards covering 48,800 shares on May 1, 2026. The Form 4 lists the acquisition price as $0.00 (derivative), indicating an option award rather than an open-market purchase or sale. This is an award (not a sale or purchase) reported as part of director compensation.

Key Details

• Transaction date: 2026-05-01; reported on the same date (filing appears timely).
• Award: Options covering 48,800 shares; reported acquisition price $0.00 (derivative).
• Vesting: Shares underlying the options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to continued service. (Footnotes: grant under non‑employee director compensation policy.)
• Shares owned after transaction: Not disclosed in the provided filing.
• No indication of immediate exercise or sale — this is a grant of options, not a cashless exercise or open‑market trade.

Context
This appears to be a routine non‑employee director compensation award under the company policy. For retail investors: option grants to directors are common and reflect compensation, not necessarily an insider buying stock in the open market. The staggered monthly vesting means the awards become exercisable over the next year, contingent on continued board service.